新創建集團(00659.HK)預計中期純利同比增長約1.5倍
格隆匯1月31日丨新創建集團(00659.HK)公佈,集團預期截至2021年12月31日止六個月期間錄得股東應占溢利較去年同期增長大致1.5倍。
集團業績大幅改善主要是由於非經營虧損中的重新計量、減值及撥備於該期間較去年同期大幅減少;及公司於2021年10月8日及2021年11月15日公佈的出售投資項目錄得淨收益,而去年同期的出售投資項目則錄得淨虧損。然而上述有利因素部份被集團於該期間的應占經營溢利較去年同期減少所抵消,這是由於(i)策略性投資業務並沒有如去年同期般因若干投資的重大公平值淨收益而提供正面貢獻;及(ii)來自以往已出售的業務或被重新分類為待售資產的業務的貢獻有所減少所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.